dilatation of volume. Acute dilatation of stomach
Conditions
Interventions
Intervention 1: Intervention group: In the first group, neostigmine, manufactured by Caspian Tamin Pharmaceutical Company, was used at 2.5 mg / 100 ml of normal saline, intravenously and one time. Int
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Age between 20 and 50 years Patients under mechanical ventilation Patients with enteral nutrition through nasogastric tube
Exclusion criteria
Exclusion criteria: Previous use of beta blockers Heart Block Bradycardia (heart rate less than 60) before inclusion Hypothermia in the form of central temperature below 35 degrees Kidney Failure (CR> 1.5) Use Erythromycin or Cisapride within 8 hours before starting the study Recent surgery on stomach or digestive tract within the last ten days Signs and symptoms of bowel obstruction Pregnancy and lactation Active bronchospasm Extrapyramidal symptoms Sensitivity to Neostigmine Active gastrointestinal bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric residual volume. Timepoint: Before starting the drug infusion and 3, 6, 9 and 12 hours after the start of the infusion. Method of measurement: Aspirate with a gavage syringe. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSara Saneie Moqadam
Zahedan University of Medical Sciences
Outcome results
None listed